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Tumor angiogenesis is the result of an imbalance between positive and negative angiogenic factors released by tumor and host cells
into the microenvironment of the neoplastic tissue. The stroma constitutes a large part of most solid tumors, and cancer-stromal
cell interactions contribute functionally to tumor growth and metastasis. Activated ﬁbroblasts and macrophages in tumor stroma
play important roles in angiogenesis and tumor progression. In gastric cancer, tumor cells and stromal cells produce various
angiogenic factors, including vascular endothelial growth factor, interleukin-8, platelet-derived endothelial cell growth factor, and
angiopoietin. In addition, Helicobacter pylori infection increases tumor cell expression of metastasis-related genes including those
encoding several angiogenic factors. We review the current understanding of molecular mechanisms involved in angiogenesis and
lymphangiogenesis of human gastric cancer.
1.Introduction
Gastric cancer is the world’s second leading cause of
cancer death [1]. In Asian countries such as Korea and
China, gastric cancer is the leading cause of cancer death.
Conventional therapies for advanced-stage gastric cancer
include surgery, chemotherapy, and radiotherapy, but the
prognosis for advanced-stage disease remains poor. Novel
therapeutic strategies are needed, but their development
dependsonunderstandingcancerbiology,especiallychanges
that occur on the molecular level. A large number of
genetic and epigenetic alterations in oncogenes and tumor
suppressor genes as well as genetic instability determine the
multistep process of gastric carcinogenesis [2]. In addition,
the molecular events that characterize gastric cancer diﬀer,
depending on the histologic type, whether intestinal- or
diﬀuse-type gastric cancer [2].
Tumor tissue, including gastric cancer, consists of both
tumor cells and stromal cells. Tumor growth and metastasis
are determined not only by tumor cells themselves but
also by stromal cells. Recent studies have shown that
interactions between tumor cells and activated stromal
cells create a unique microenvironment that is crucial for
tumor growth and metastasis (Figure 1)[ 3, 4]. The organ-
speciﬁc microenvironment can inﬂuence the growth, vas-
cularization, invasion, and metastasis of human neoplasms
[5].
Angiogenesis and lymphangiogenesis are both essential
for tumor growth and metastasis. Increased vascularity
enhances the growth of primary neoplasms by supplying
nutrients and oxygen, and it provides an avenue for hema-
togenous metastasis [6, 7]. Weidner et al. [8]ﬁ r s tr e p o r t e d
a direct correlation between the incidence of metastasis and
the number and density of blood vessels in invasive breast
cancers. Similar studies have conﬁrmed this correlation in
gastrointestinal cancers [9–12]. Induction of angiogenesis
is mediated by a variety of molecules released by tumor
c e l l sa sw e l la sh o s ts t r o m a lc e l l s[ 6, 7]. Clinical prognosis
depends on whether lymph node metastasis has occurred.
The growth of lymphatic vessels (lymphangiogenesis) in
the tumor periphery correlates with lymphatic metastasis
in cases of gastric cancer [13, 14]. Lymphangiogenesis is
regulated by members of the vascular endothelial growth
factor (VEGF) family and their receptors. Herein, we discuss
the role of angiogenic and lymphangiogenic fact-ors in the
growth and metastasis of human gastric cancer.2 Journal of Oncology
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Figure 1: Interaction between gastric cancer cells and stromal cells inﬂuences angiogenesis and lymphangiogenesis through various
angiogenic factors and cytokines.
2. Tumor Angiogenesisin GastricCancer
2.1. VEGF-A. Gastric cancer cells produce various angio-
genic factors. Of these, VEGF (now termed VEGF-A) is
considered one of the strongest promoters of angiogenesis of
gastrointestinal tumors [15]. VEGF-A is released by cancer
cells. Fibroblasts and inﬂammatory cells in tumor stroma
are also sources of host-derived VEGF-A [16]. VEGF-A, also
known as vascular permeability factor, is a secreted protein
thatmay,inaddition,playapivotalroleinhyperpermeability
of the vessels [17]. Several groups of investigators have
reported a correlation between VEGF-A expression and
microvessel density (MVD) of human gastric cancer [11,
18, 19]. VEGF-A-positive tumors have been shown to have
a poorer prognosis than that of VEGF-A-negative tumors
[10, 12, 20].
The prognosis of gastric cancer depends on both his-
tologic type and disease stage [21]. Intestinal-type gastric
cancer tends to metastasize to the liver in a hematogenous
manner. In contrast, diﬀuse-type gastric cancer is more
invasive; dissemination is predominantly peritoneal. Factors
responsible for liver metastasis and peritoneal dissemination
have not yet been identiﬁed, however, we have found that
the angiogenic phenotype diﬀers between intestinal-type
and diﬀuse-type gastric cancers [11, 19]. In comparison
to diﬀuse-type gastric cancer, the intestinal-type is more
dependent on angiogenesis. Intestinal-, but not diﬀuse-type,
tumors have been shown to express high levels of VEGF-A,
and the level of VEGF-A expression correlates signiﬁcantly
with vessel count [11, 19]. In contrast, ﬁbroblast growth
factor (FGF)-2 expression is higher in diﬀuse-type tumors,
especiallyscirrhous-typetumors[22].Theseﬁndingssuggest
that VEGF-A promotes angiogenesis and progression of
humangastriccancers,especiallythoseoftheintestinal-type.
Peripheral blood VEGF-A levels, that is, serum and/or
plasma concentrations of VEGF-A, have been examined in
patients with malignant disease. Ohta et al. [23] examined
VEGF-A levels in peripheral blood and the tumor drainage
vein and then evaluated these in relation to clinicopathologic
features of gastric cancer. They found that the peripheral
blood plasma VEGF-A level is increased in patients with
venous invasion and that the increase correlates with lymph
node metastasis. The level of VEGF-A in plasma from
peripheral veins is a sensitive marker for the progression of
gastric cancer.
2.2. Interleukin (IL)-8. IL-8 is a multifunctional cytokine
that can stimulate division of endothelial cells. IL-8 can
induce migration of some tumor cells [24] and has been
implicated in the induction of angiogenesis in such diverse
diseases as psoriasis and rheumatoid arthritis and in some
malignantdiseases.IL-8isaknownangiogenicfactorpresent
in human lung cancer [25, 26] and is also produced by
melanomas [27]a n db l a d d e r[ 28] and prostate [29]c a n c e r s .
We examined expression of IL-8 in human gastriccancer and
found that most tumor tissues express IL-8 at levels higher
than those in the corresponding normal mucosa [29, 30].
The IL-8 mRNA level in neoplasms correlates strongly with
vascularization, suggesting that IL-8 produced by tumor
cells regulates neovascularization. To provide evidence forJournal of Oncology 3
a causal role of IL-8 in angiogenesis and tumorigenicity
of human gastric cancer, we introduced the IL-8 gene into
several human gastric cancer cell lines. Gastric cancer cells
transfected with the IL-8 gene and injected orthotopically
into the gastric wall of nude mice produce fast-growing,
highly vascular neoplasms [31].
Gastric cancer cells express not only IL-8 but also IL-8
receptor A (CXCR1) and IL-8 receptor B (CXCR2) [32]. In
vitro treatment of human gastric cancer cells (MKN-1 cells)
with exogenous IL-8 enhances the expression of epidermal
growth factor receptor (EGFR), matrix metalloproteinase
(MMP)-9, VEGF-A, and IL-8 mRNAs. In contrast, such
treatment decreases expression of E-cadherin mRNA. IL-8
treatment increases the invasive capacity of gastric cancer
cells, and IL-8 expression is associated with MMP-9 activity.
Collectively, these ﬁndings indicate that human gastric
cancer cells express receptors for IL-8 and that IL-8 may
have autocrine/paracrine roles in the progressive growth of
human gastric cancer.
The prognosis for patients with gastric cancer expressing
high levels of IL-8 and VEGF-A is signiﬁcantly poorer than
that for patients whose tumors express low levels [20]. A
high level of IL-8 in the drainage vein of gastric cancer is
associated signiﬁcantly with a relatively short disease-free
survival period [33].
2.3. Platelet-Derived Endothelial Cell Growth Factor (PD-
ECGF). PD-ECGF, an endothelial cell mitogen that was
initially puriﬁed to homogeneity from human platelets, has
chemotactic activity for endothelial cells in vitro and is
angiogenic in vivo [34]. PD-ECGF was shown to be identical
to thymidine phosphorylase, an enzyme involved in pyrim-
idine nucleoside metabolism [35]. PD-ECGF expression is
elevated in several types of solid tumor including colon
cancer [36, 37]. We reported that PD-ECGF is associated
with angiogenesis of human colon cancer [38]. PD-ECGF
is expressed at high levels in vascular tumors that express
low levels of VEGF-A [38]. In such colon cancers, the major
source of PD-ECGF is the inﬁltrating cells. A positive associ-
ation between PD-ECGF expression and MVD has also been
reported for human gastric cancer [39–41]. In human gastric
cancer, PD-ECGF is expressed more frequently in inﬁltrating
cells than in tumor epithelium [39]. An association exists
between PD-ECGF expression by inﬁltrating cells, VEGF-
A expression by tumor epithelium, and vessel counts in
intestinal-type gastric cancer but not in diﬀuse-type gastric
cancer [39].
2.4. Angiopoietin. The angiopoietin family growth factors
have been identiﬁed as ligands for Tie-2. Angiopoietin-
1 activates Tie-2, leading to receptor autophosphorylation
upon binding, and it simulates endothelial cell migration
in vitro and contributes to blood vessel stabilization by
recruitment of pericytes [42]. Angiopoietin-2 is a natural
antagonist for Tie-2 receptor [43]. As such, it antagonizes
angiopoietin-1-vessel maturation and regulates blood vessel
growth, regression, or sprouting, depending on the presence
of VEGF [43]. VEGF-A/VEGFR2 is mainly involved in the
initiation of angiogenesis, whereas the angiopoietin/Tie2
system is related to remodeling and maturation of vessels
[44]. Angiopoietin-1 and -2 are reported to be highly
expressed in human gastric cancer [45, 46]. Inhibition of
angiopoietin-1 by antisense expression vector was shown
to reduce tumorigenesis and angiogenesis of gastric cancer
xenografts in nude mice [47]. Production of angiopoietin-
2 also contributes to tumor angiogenesis of gastric cancer
in the presence of VEGF by induction of proteases in
endothelial cells [48].
3. Tumor Lymphangiogenesis inGastricCancer
The VEGF family includes VEGF-A, -B, -C, -D, -E, and
-F and placental growth factor (PlGF) [49]. VEGF-C and
VEGF-D are ligands for VEGF receptor (VEGFR)-3 and
VEGFR-2. VEGFR-3 is a tyrosine kinase receptor, that is,
expressed predominantly in the endothelium of lymphatic
vessels [50]. Skobe et al. [51] described VEGF-C as a lym-
phangiogenicfactorthatcanselectivelyinducehyperplasiaof
the lymphatic vasculature. A signiﬁcant correlation between
lymph node metastasis and VEGF-C expression has been
reported in gastric cancer [13, 14]. Onogawa et al. [52]
examined expression of VEGF-C and VEGF-D by immuno-
histochemistry in 140 archival surgical specimens of submu-
cosally invasive gastric cancer. VEGF-C immunoreactivity
was associated with lymphatic invasion, lymph node metas-
tasis, and increased MVD. There was no association between
VEGF-D immunoreactivity and clinicopathologic features.
These results suggest that VEGF-C is a dominant regulator
of lymphangiogenesis in early-stage human gastric cancer.
VEGFRs are expressed by a wide variety of cancer cell
lines. VEGF-A and VEGFR-1/2 are coexpressed in a number
of cancers, including cancers of the breast [53], prostate [54],
colon [55], and pancreas [56, 57], suggesting that VEGF-
A directly inﬂuences tumor cell growth via an autocrine
mechanism.VEGFR-3hasalsobeendetectedonseveraltypes
of malignant cells, although the signiﬁcance of such expres-
sion remains unclear. We recently examined the expression
and function of VEGFR-3 in gastric cancer cells [58]. In
vitro treatment of gastric cancer cell line KKLS, which
expresses VEGFR-3, with the ligand of this receptor, VEGF-
C, stimulated cell proliferation and increased expression of
mRNAs encoding cyclin D1, PlGF, and autocrine motility
factor [58]. Thus, VEGF-C may act in both an autocrine
fashion and paracrine fashion to promote angiogenesis and
further the growth of human gastric cancer.
O t h e rg r o w t hf a c t o r sa r er e p o r t e dt ob el y m p h a n g i o -
genic, such as FGF-2 [59] and platelet-derived growth factor
(PDGF)-BB [60]. The lymphangiogenic eﬀect of FGF-2
appears to be indirect, that is, it occurs via VEGF-C or -D.
WerecentlyfoundthatgastriccancercellsproducePDGF-BB
and that dilated lymphatics in the tumor periphery express
PDGF receptor-β (Kodama et al., unpublished data), sug-
gesting that PDGF-BB is a regulator of lymphangiogenesis in
gastric cancer. Angiopoietin-2 is crucial for establishing the
lymphatic vasculature. VEGF-C/VEGFR-3 signaling is a key
primary proliferation pathway for lymphatic vessels, whereas
angiopoietin-2 is importantin later remodeling stages [61].4 Journal of Oncology
The importance of FGF-2, PDGF-BB, and angiopoietin-2
for lymphatic metastasis of human gastric cancer is still
unknown.
4. Tumor-Stromal Cell Interactionin
Tumor Angiogenesis
Tumor stroma consists of activated ﬁbroblasts (myoﬁbrob-
lasts), smooth muscle cells, endothelial cells, and inﬂamma-
tory cells, including macrophages. Macrophages migrating
to tumor stroma are called tumor-associated macrophages
(TAMs). The role of TAMs in tumor progression is compli-
cated. Although activated macrophages may have antitumor
activity, tumor cells are reported to escape the antitumor
activity of TAMs [62]. It has become clear that TAMs are
active players in the process of tumor progression and inva-
sion. Indeed, removal of macrophages by genetic mutation
has been shown to reduce tumor progression and metastasis
[63]. One important characteristic of macrophages is the
potential for angiogenic activity. Activated macrophages
produce various factors that induce angiogenesis in wound
repair [64] and in chronic inﬂammatory diseases [65,
66]. Upon activation by cancer cells, TAMs can release
diverse growth factors, proteolytic enzymes, and cytokines.
In clinical studies, high numbers of TAMs have been
shown to correlate with high vessel density and tumor
progression [67–69]. We previously reported that TAM
inﬁltration into tumor tissue correlates signiﬁcantly with
tumor vascularity in human esophageal and gastric cancers
[67, 68]. Ishigami et al. [69] also found direct associations
between the degree of TAM inﬁltration and depth of tumor
invasion, nodal status, and clinical stage in cases of gastric
cancer. Macrophage recruitment is mediated by a variety
of chemoattractants, including monocyte chemoattractant
protein-1 (MCP-1/CCL2) and macrophage inﬂammatory
protein 1α (MIP-1α/CCL3). Of the CC chemokines, MCP-
1 is one of the most potent [70]. We found that MCP-
1 produced by tumor cells is associated signiﬁcantly with
macrophage inﬁltration and malignant behavior, such as
angiogenesis,tumorinvasion, andlymphaticinﬁltration[67,
68]. Transfection of the MCP-1 gene into gastric cancer
cells was shown to cause strong inﬁltration of macrophages
into tumors and enhanced tumorigenicity and metastatic
potential in a mouse orthotopic implantation model [71].
BecauseactivatedmacrophagesproduceVEGF-A,IL-8,FGF-
2, and PD-ECGF, MCP-1 expressed by gastric cancer cells
plays a role in angiogenesis via recruitment and activation
of macrophages.
Activated ﬁbroblasts in cancer stroma are prominent
modiﬁers of tumor progression and are therefore called
cancer-associated ﬁbroblasts (CAFs) [72, 73]. CAFs have
gene expression proﬁles that are distinct from those of nor-
mal ﬁbroblasts [74], and they acquire a modiﬁed phenotype,
similar to that of ﬁbroblasts associated with wound healing.
Tumor tissue contains abundant growth factors, cytokines,
and matrix-remodeling proteins; thus, tumors are likened
to wounds that never heal [75]. Although the mechanisms
that regulate activation of ﬁbroblasts in tumors are not fully
understood, PDGF, transforming growth factor-β, and FGF-
2 are known to be partly involved [72, 73, 76]. We previously
reportedthatCAFsandpericytesexpressPDGFreceptor,and
targeting the PDGF receptor on stromal cells inhibits growth
and metastasis of human colon cancer [76, 77]. Therefore,
CAFs might serve as novel therapeutic targets in cancer
patients.
5.Helicobacter pylori (H. pylori) Stimulates
Angiogenesis of GastricCancer
A recent advance in understanding the pathogenesis of
gastric cancer is recognition of the role of H. pylori in gastric
carcinogenesis. H. pylori infection is thought to contribute
signiﬁcantly to the pathogenesis of atrophic gastritis, intesti-
nal metaplasia, and peptic ulcer. Epidemiologic studies have
indicated that infection with H. pylori is a risk factor for
gastric cancer, and in 1994 the WHO/IARC classiﬁed this
bacterium as a deﬁnite biologic carcinogen [78]. In addition,
inoculation of the stomach of Mongolian gerbils with H.
pylori was shown to be associated with the occurrence of
chronic gastritis, intestinal metaplasia, and adenocarcinoma
[79, 80]. A recent study showed that H. pylori penetrates
normal, metaplastic, and neoplastic epithelia to cause a
strong immune-inﬂammatory response and promote gastric
carcinogenesis [81]. H. pylori is a potent activator of nuclear
factor-kB (NF-kB) in gastric epithelial cells. Activation of
NF-kB by H. pylori infection induces a variety of cytokines,
angiogenic factors, MMPs, and adhesion molecules [82, 83].
The relation between H. pylori infection and angiogenesis
has been studied increasingly over the past few years. We
reported previously that H. pylori-infected gastric cancer
patients show greater tumor vascularity than that of gastric
cancer patients after H. pylori eradication [84], suggesting
that H. pylori infection inﬂuences angiogenesis of gastric
cancer. Some studies suggested that the cagA-positive H.
pylori strain plays an important role in tissue remodeling,
angiogenesis, cancer invasion, and metastasis [85–87]. Crab-
tree et al. [85] reported that H. pylori infection induces IL-8
production by gastric epithelium. We found that coculture
of gastric cancer cells with H. pylori induces expression of
mRNAsencodingIL-8,VEGF-A,angiogenin,urokinase-type
plasminogen activator, and MMP-9 by gastric cancer cells
[86]. Wu et al. [87] also reported that H. pylori inﬂuences
expression of VEGF-A and MMP-9 and promotes gastric
cell invasion via COX-2- and NF-kB-mediated pathways.
Expression of COX-2 was found to correlate signiﬁcantly
with VEGF expression and MVD in gastric cancer [88, 89].
6. Antiangiogenic Therapy Against
GastricCancer
A novel category of anticancer drugs, “molecular-targeted
drugs”, has become available. Angiogenesis is considered
one of the most important molecular targets for anticancer
therapy because it is essential for tumor growth and
metastasis. VEGF is one of the most potent angiogenic
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investigated, such as colorectal, esophageal, gastric, lung,
breast, renal, and ovarian cancers [9, 12, 15, 90]. In these
cancers, expression of VEGF correlates with advanced stage
disease and poor prognosis. Therefore, inhibiting VEGF is
a rational strategy for treating cancer [91]. Bevacizumab
is a humanized monoclonal antibody that targets VEGF.
Signiﬁcant prolonged survival has been reported in patients
with metastatic colorectal cancer treated with bevacizumab
in combination with cytotoxic chemotherapy [92]. Similar
improvementwereobserved inpatients withbreastandnon-
small cell lung cancers. A randomized trial evaluating the
eﬃcacy of this agent in patients with gastric cancer (the
AVAGAST study) is now being conducted internationally;
Japan and Korea are included [93]. Several other strategies
targeting the VEGF signaling pathway have been developed,
including use of soluble receptors binding directly to VEGF
ligand, anti-VEGFR antibodies, and VEGR tyrosine kinase
inhibitors. These next-generation targeted agents are being
evaluated in early clinical studies [91, 93].
7.FuturePerspectives
Tumor cells are genetically unstable and biologically hetero-
geneous, and these are the principal causes of the failure of
systemic chemotherapies. It has been believed that endothe-
lial cells and CAFs in tumor stroma are genetically stable and
that these cells will not become drug resistant in response
to antivascular therapy. However, recent studies showed that
endothelial cells in certain tumor vessels are aneuploid and
that they express neoplastic markers [94]. Recently, investi-
gators have come to appreciate the signiﬁcance of other cell
types, such as pericytes and vascular smooth muscle cells,
that make up vascular structures and are essential for the
function and survival of endothelial cells. The structure and
function of vessels diﬀer in diﬀerent tissues and in tumors
at diﬀerent sites. Inhibition of activated stromal cell com-
ponents including TAMs and CAFs may eﬀectively alter the
tumor microenvironment involved in tumor angiogenesis
and progression. Understanding the cellular and molecular
mechanisms that regulate vascularization of tumors may
facilitate development of eﬀective antivascular therapies.
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